NCT02503709View on ClinicalTrials.gov

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

August 15, 2020

Study Completion Date

October 9, 2020

Conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Solid Neoplasm
Interventions
DRUG

CDK Inhibitor AT7519

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Onalespib

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (6)

20007

MedStar Georgetown University Hospital, Washington D.C.

20892

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

National Institutes of Health Clinical Center, Bethesda

43210

Ohio State University Comprehensive Cancer Center, Columbus

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02503709 - Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter